Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Combination treatment of SSZ and DFMO in SK-N-Be(2)c and LAN-5 cells for 48 h

From: Effect of sulfasalazine on human neuroblastoma: analysis of sepiapterin reductase (SPR) as a new therapeutic target

  Concentration, IC50 Equivalent     
NB Cell Line SSZ DFMO Combination Index at 50 % Effect Level Evaluation at 50 % Effect Level SSZ IC50 (μM) DFMO (mM)
SK-N-Be(2)c 0.408 0.425 0.834 slight synergism 54.360 1.800
  0.223 0.614 0.837 slight synergism 29.640 2.600
  0.314 0.803 1.117 moderate antagonism 41.740 3.400
  0.140 0.992 1.132 moderate antagonism 18.700 4.200
  0.415 1.181 1.595 antagonism 55.180 5.000
LAN-5 0.004 0.207 0.211 strong synergism 1.207 1.200
  0.173 0.311 0.484 synergism 58.250 1.800
  0.015 0.466 0.482 synergism 5.152 2.700
  0.439 0.691 1.130 moderate antagonism 147.900 4.000
  0.003 1.037 1.039 additive 0.893 6.000
  1. Legend: The concentration in IC50 equivalent of SSZ was calculated by dividing the IC50 of SSZ with DFMO combination from its corresponding single-agent IC50 value (IC50 of SSZ w/ DFMO comb/SSZ IC50). For DFMO, the concentration in IC50 equivalent was calculated by dividing its actual concentration used in the combination treatment from its corresponding single-agent IC50 value (DFMO/ DFMO IC50). Combination index (CI) at 50 % effect level is calculated by adding the IC50 equivalent concentration of SSZ and DFMO. CI >1.3 is antagonism; CI = 1.1-1.3 is moderate antagonism; CI = 0.9-1.1 is additive; CI = 0.8-0.9 is slight synergism; CI = 0.6-0.8 is moderate synergism; CI = 0.4-0.6 is synergism; CI = 0.2-0.4 is strong synergism. Synergism was detected at two different combinations of DFMO and SSZ in SK-N-Be(2)c cells and three different combinations in LAN-5 cells (bold italics). The data present the average of three independent experiments performed in duplicate (n = 6)